NDC 50090-1377-1 Boostrix

Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine, Adsorbed

NDC Package Code 50090-1377-1

The NDC Code 50090-1377-1 is assigned to a package of 1 syringe in 1 pouch > .5 ml in 1 syringe of Boostrix, a vaccine lable labeled by A-s Medication Solutions. The product's dosage form is suspension and is administered via intramuscular form.

Field Name	Field Value
NDC Code	50090-1377-1
Package Description	1 SYRINGE in 1 POUCH > .5 mL in 1 SYRINGE
Proprietary Name	Boostrix What is the Proprietary Name? The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name	Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine, Adsorbed What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format	50090137701 NDC Format for Billing For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit	ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Product Type	Vaccine What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name	A-s Medication Solutions
Dosage Form	Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route(s)	Intramuscular - Administration within a muscle.
Active Ingredient(s)	CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) 5 [iU]/.5mL CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) 2.5 [iU]/.5mL BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) 8 ug/.5mL BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) 8 ug/.5mL BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) 2.5 ug/.5mL
Pharmacological Class(es)	Inactivated Clostridium Tetani Vaccine - [EPC] (Established Pharmacologic Class) Actively Acquired Immunity - [PE] (Physiologic Effect) Vaccines - Inactivated - [CS] Tetanus Toxoid - [CS] Inactivated Corynebacterium Diphtheriae Vaccine - [EPC] (Established Pharmacologic Class) Actively Acquired Immunity - [PE] (Physiologic Effect) Vaccines - Inactivated - [CS] Diphtheria Toxoid - [CS] Inactivated Bordetella Pertussis Vaccine - [EPC] (Established Pharmacologic Class) Actively Acquired Immunity - [PE] (Physiologic Effect) Pertussis Vaccine - [CS] Vaccines - Inactivated - [CS] Pertussis Vaccine - [CS] Inactivated Bordetella Pertussis Vaccine - [EPC] (Established Pharmacologic Class) Actively Acquired Immunity - [PE] (Physiologic Effect) Vaccines - Inactivated - [CS] Inactivated Bordetella Pertussis Vaccine - [EPC] (Established Pharmacologic Class) Actively Acquired Immunity - [PE] (Physiologic Effect) Vaccines - Inactivated - [CS] Pertussis Vaccine - [CS]
Sample Package	No Sample Package? This field Indicates whether this package is a sample packaging or not.
Marketing Category	BLA - A product marketed under an approved Biologic License Application. What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number	BLA125106 What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date	07-24-2009 What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date	12-31-2022 What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag	N What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

NDC Code Structure

50090 - A-s Medication Solutions
- 50090-1377 - Boostrix
  - 50090-1377-1 - 1 SYRINGE in 1 POUCH

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Boostrix with product NDC 50090-1377.

NDC Package Code	Package Description
50090-1377-0	10 SYRINGE in 1 CARTON > .5 mL in 1 SYRINGE (50090-1377-9)

* Please review the disclaimer below.

Previous Code: 50090-1375

Next Code: 50090-1380